Eyal Fruchter, Nadav Goldenthal, Lenard A Adler, Raz Gross, Eiran V Harel, Lisa Deutsch, Nitsa Nacasch, Shulamit Grinapol, Daniela Amital, Jeffrey D Voigt, Charles R Marmar
We conducted a prospective, single arm, multisite, multinational, open label trial assessing the safety and efficacy of a novel amygdala derived neurofeedback treatment, designated Amygdala-Derived-EFP, for chronic PTSD. Participants, including veterans and civilians, underwent screening, training, 15 neurofeedback sessions over 8 weeks and; baseline, termination (8 weeks) and 3 month post treatment assessments with validated measures. The primary endpoint was more than 50 % of the participants demonstrating a Minimally Clinically Important Difference (MCID) defined as a 6-point reduction, on the Clinician Administered PTSD Scale (CAPS-5) total score at 3 months...
January 8, 2024: Psychiatry Research